Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Repatha Cancer Risk Signal Review: What the Evidence Actually Shows

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug / evolocumab (Repatha), a PCSK9 inhibitor given by subcutaneous injection [1]
  • Cancer warning in the label / none; the only Warning and Precaution is hypersensitivity including angioedema [1]
  • Largest trial / FOURIER, 27,564 adults with atherosclerotic cardiovascular disease, median 2.2 years [2]
  • Longest follow-up / FOURIER-OLE, 6,635 patients, median 5.0 years, up to 8.4 years of evolocumab [4]
  • Second large trial / VESALIUS-CV, 12,257 adults, no between-group difference in safety events [3]

Does the Repatha label list cancer as a risk?

No. The label has no boxed warning; its only Warning and Precaution covers hypersensitivity reactions, including angioedema, and its only contraindication is a history of a serious hypersensitivity reaction [1]. Evolocumab was approved on 27 August 2015 and is labeled to reduce major adverse cardiovascular events in adults at increased risk and to lower LDL cholesterol in hypercholesterolemia, HeFH and HoFH from age 10 [1][5].

What FOURIER reported

FOURIER randomized 27,564 adults with atherosclerotic cardiovascular disease and LDL cholesterol of 70 mg/dL or higher on a statin to evolocumab 140 mg every two weeks or 420 mg monthly, or to placebo, for a median of 2.2 years [2]. The primary cardiovascular composite occurred in 1,344 patients (9.8%) on evolocumab and 1,563 (11.3%) on placebo, hazard ratio 0.85 (95% CI 0.79 to 0.92) [2]. LDL cholesterol fell from a median of 92 mg/dL to 30 mg/dL, a 59% reduction versus placebo at 48 weeks [2].

Longer exposure: FOURIER-OLE

FOURIER-OLE enrolled 6,635 patients from participating FOURIER sites, with a median follow-up of 5.0 years and maximum cumulative evolocumab exposure of 8.4 years [4]. Long-term incidences of serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke and neurocognitive events did not exceed those for placebo-treated patients in the parent study and did not increase over time [4].

VESALIUS-CV randomized 12,257 adults with atherosclerosis or diabetes and no previous myocardial infarction or stroke to evolocumab 140 mg every two weeks or placebo, and found no evidence of a between-group difference in safety events [3].

Statin trials and cancer: a different drug class

For context, a meta-analysis of 35 randomized statin trials with 109,143 patients found no substantial increase or decrease in overall cancer risk (relative risk 0.99, 95% CI 0.94 to 1.04) over an average of 4.5 years [6]. Those trials tested statins, which lower LDL by inhibiting HMG-CoA reductase, not PCSK9 antibodies, so they do not measure evolocumab's effect.

Frequently asked questions

Does Repatha cause cancer?
The Repatha label carries no cancer warning or precaution; its only Warning and Precaution is hypersensitivity including angioedema [1]. In FOURIER-OLE, the events named as not exceeding placebo were serious adverse events, muscle events, new-onset diabetes, hemorrhagic stroke and neurocognitive events [4].
What did the FOURIER trial report on safety?
Over a median 2.2 years, FOURIER reported the cardiovascular composite (hazard ratio 0.85) and a 59% LDL cholesterol reduction versus placebo at 48 weeks [2]. There was no significant difference in adverse events except injection-site reactions, 2.1% on evolocumab versus 1.6% on placebo [2].
How long have patients been followed on evolocumab?
FOURIER-OLE followed 6,635 patients for a median of 5.0 years, with maximum cumulative exposure of 8.4 years [4].
Is a cancer history a contraindication to evolocumab?
The label's only contraindication is a history of a serious hypersensitivity reaction to evolocumab or any excipient [1].

References

  1. DailyMed - REPATHA- evolocumab injection, solution. DailyMed - REPATHA- evolocumab injection, solution
  2. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  3. Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117-127. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
  4. O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146(15):1109-1119. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
  5. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  6. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006;24(30):4808-17. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials
Evidence overview for Repatha Cancer Risk Signal Review: What the Evidence Actually Shows